Products

Below you will find information on Amgen’s product portfolio. Prescribing information and patient information leaflets for each product can be downloaded through the links. These links direct you straight to the Electronic Medicines Compendium (eMC); a resource providing information about all medicines available in the UK.

Please note that this information is specific to the UK, and is not intended to replace the advice of a qualified doctor. For information on our products in Ireland please visit www.medicines.ie




Aranesp® (darbepoetin alfa)

Aranesp® (darbepoetin alfa) is indicated for the treatment of symptomatic anaemia associated with chronic renal failure in adults and paediatric patients and the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Aranesp® is available in a pre-filled syringe or in a pre-filled pen.

Aranesp - UK Summary of Product Characteristics and Patient Information Leaflets





 

Mimpara® (cinacalcet HCl)

Mimpara® (cinacalcet) is approved for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. It is also approved for the reduction of hypercalcaemia in patients with:

  • Parathyroid carcinoma
  • Primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated

Mimpara - UK Summary of Product Characteristics and Patient Information Leaflets




 

Neupogen® (filgrastim)

Neupogen® (filgrastim) is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adults and children treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.

Neupogen® is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).

In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an ANC of  0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Neupogen® is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.

Neupogen® is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Neupogen® is available in vials and prefilled syringes.

Neupogen - UK Summary of Product Characteristics and Patient Information Leaflets 





 

Neulasta® (pegfilgrastim)

Neulasta® (pegfilgrastim) is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Neulasta is a longer-acting version of Neupogen® and requires only one injection per chemotherapy cycle.

Neulasta® is available in pre-filled syringes with an automatic needle guard.

Neulasta - UK Summary of Product Characteristics and Patient Information Leaflets 





 

Nplate® (romiplostim)

Nplate® (romiplostim) is approved for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate® may be considered as second line treatment for adult non-splenectomised patients where surgery is contraindicated.

Nplate - UK Summary of Product Characteristics and Patient Information Leaflets
 

Prolia® (denosumab)

Prolia® (denosumab) is approved for the treatment of osteoporosis in postmenopausal women at the risk for fractures. It is also approved for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

Prolia - UK Summary of Product Characteristics and Patient Information Leaflets





 

Vectibix® (panitumumab)

Vectibix® (panitumumab) is indicated as monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR) expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Vectibix - UK Summary of Product Characteristics and Patient Information Leaflets





 

XGEVA® (denosumab)

XGEVA® (denosumab) is approved for the prevention of skeletal related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.

XGEVA - UK Summary of Product Characteristics and Patient Information Leaflets





 

Total of 8 Products

Amgen is committed to patient safety and continually monitors the safety and quality of our products.

Adverse events and product quality issues should be reported.

For the UK - reporting forms and information can be found at http://www.yellowcard.gov.uk/

For Ireland - reporting forms and information can be found at http://www.imb.ie/

Adverse events and product quality issues should also be reported to Amgen.

To report a potential adverse event or quality issue with an Amgen product, or for medical information enquiries, please call +44 (0) 1223 436441 (UK and Ireland)